MedTrace Logo

Adequacy of Perioperative Cefuroxime Dosage According to the BMI

NCT03141476 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-02-20

No results posted yet for this study

Summary

This study evaluates the dosage of perioperative cefuroxime for obese patients. Dosage was increased if the BMI was over 30kg/m\*m and as well over 50kg/m\*m. Drug levels were measured in blood and tissue.

Conditions

  • Obesity; Drug

Interventions

DRUG

Cefuroxime 1,5g

Patients with BMI of \<30kg/m\*m: 1,5 g Cefuroxime

DRUG

Cefuroxime 3g

Patients with BMI of 30-50kg/m\*m: 3g Cefuroxime

DRUG

Cefuroxime 4,5g

Patients with BMI of \>50kg/m\*m: 4,5 g Cefuroxime

Sponsors & Collaborators

  • Universitätsklinikum Hamburg-Eppendorf

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2017-11-12
Completion
2017-12-12

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03141476 on ClinicalTrials.gov